Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.49 |
| ▸ | JAK2 | O60674 | 5/20 | 0.48 |
| ▸ | JAK1 | P23458 | 5/20 | 0.48 |
| ▸ | TYK2 | P29597 | 4/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 4/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079361 | 0.88 | JAK3 (0.50) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL323196 | 0.85 | KIT (0.58) | JAK3JAK2JAK1TYK2KIT | |
| SCHEMBL327142 | 0.85 | JAK3 (0.56) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL323147 | 0.84 | JAK3 (0.50) | JAK3JAK2JAK1TYK2KIT | |
| SCHEMBL323477 | 0.84 | KIT (0.57) | JAK3JAK2JAK1TYK2KIT | |
| SCHEMBL323725 | 0.82 | JAK3 (0.51) | JAK3JAK2JAK1TYK2KIT | |
| SCHEMBL322965 | 0.82 | JAK3 (0.48) | JAK3JAK2JAK1TYK2KIT | |
| SCHEMBL323130 | 0.81 | JAK3 (0.50) | JAK3JAK2JAK1TYK2KIT | |
| SCHEMBL1080417 | 0.81 | JAK3 (0.51) | JAK3AKT1LCKROCK2AKT2 | |
| SCHEMBL324516 | 0.80 | JAK3 (0.59) | JAK3JAK2JAK1TYK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | claimed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | claimed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | claimed |
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | claimed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | claimed |
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | disclosed |
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | disclosed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | JAK3 3/4885JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.